Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01576692 · ClinicalTrials.gov registry record · Phase 1
Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma
A Phase 1 study, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT01576692 is a Phase 1 study that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 34 participants.
The verdict
NCT01576692, a Phase 1 study, has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
This is a safety / feasibility trial evaluating the combination of a humanized anti-GD2 antibody (HU14.18K322A) manufactured at the Children's GMP, LLC at St. Jude with allogeneic natural killer (NK) cells and standard chemotherapy in children with relapsed or refractory neuroblastoma.
Interventions
- DRUG Chemotherapy
- DEVICE CliniMACS
- BIOLOGICAL Natural killer cells
- BIOLOGICAL Humanized anti-GD2 antibody
- OTHER Cytokines
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2012-04 |
| Est. Completion | 2018-10-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01576692
The ClinicalTrials.gov registry entry for NCT01576692 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Chemotherapy is the first listed.
NCT01576692 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01576692 about?
NCT01576692 is a clinical study titled "Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma". This is a safety / feasibility trial evaluating the combination of a humanized anti-GD2 antibody (HU14.18K322A) manufactured at the Children's GMP, LLC at St. Jude with allogeneic natural killer (NK) cells and standard chemotherapy in children with relapsed or refractory neuroblastoma.
What is the current status of trial NCT01576692?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2012-04. Estimated completion is 2018-10-17.
What interventions are being tested in trial NCT01576692?
The interventions under investigation include: Chemotherapy (DRUG), CliniMACS (DEVICE), Natural killer cells (BIOLOGICAL), Humanized anti-GD2 antibody (BIOLOGICAL), Cytokines (OTHER).
Who is sponsoring clinical trial NCT01576692?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.